Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Proteoglycans have been investigated for their potential role in supporting or treating rheumatoid arthritis (RA), largely based on their importance in cartilage structure and joint health. In RA, the degradation of cartilage is a hallmark feature, and since proteoglycans are major components of the cartilage extracellular matrix, their supplementation has been hypothesized to help restore or protect joint integrity. Some preclinical studies in animal models have shown that orally administered proteoglycans, such as those derived from salmon cartilage, can suppress inflammation and reduce joint destruction by modulating immune responses and inhibiting pro-inflammatory cytokines. However, evidence in humans is limited.

A small number of clinical studies have explored the effects of oral proteoglycan supplementation in patients with RA. For example, a pilot study published in Modern Rheumatology (2010) reported that salmon cartilage proteoglycan supplementation resulted in some reduction in disease activity and inflammatory markers in RA patients. Nevertheless, these studies are typically small, open-label, or lack rigorous controls. Systematic reviews and guidelines do not currently endorse proteoglycans as a standard treatment for RA, and more robust, large-scale clinical trials are needed to confirm benefits.

In summary, there is preliminary scientific evidence, primarily from animal studies and limited human trials, suggesting that proteoglycans may have a role in modulating inflammation and protecting cartilage in RA. However, the current level of evidence is low, and their use is not established in standard clinical practice.

More about Proteoglycans
More about Rheumatoid Arthritis

Other ingredients used for Rheumatoid Arthritis

Other health conditions supported by Proteoglycans

Products containing Proteoglycans